Kilitch Drugs (India) Performance
| KILITCH Stock | 310.65 3.25 1.06% |
The company secures a Beta (Market Risk) of -0.18, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Kilitch Drugs are expected to decrease at a much lower rate. During the bear market, Kilitch Drugs is likely to outperform the market. At this point, Kilitch Drugs Limited has a negative expected return of -0.0902%. Please make sure to verify Kilitch Drugs' potential upside, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Kilitch Drugs Limited performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Kilitch Drugs Limited has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, Kilitch Drugs is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders. ...more
Ex Dividend Date 2019-09-20 |
1 | KILITCH DRUGS Share Price Today Up 6 percent - Equitymaster | 09/10/2024 |
2 | Kilitch Drugs Standalone September 2024 Net Sales at Rs 45.35 crore, up 43.63 percent Y-o-Y - Moneycontrol | 11/13/2024 |
| Begin Period Cash Flow | 198.5 M |
Kilitch |
Kilitch Drugs Relative Risk vs. Return Landscape
If you would invest 33,280 in Kilitch Drugs Limited on August 30, 2024 and sell it today you would lose (2,540) from holding Kilitch Drugs Limited or give up 7.63% of portfolio value over 90 days. Kilitch Drugs Limited is generating negative expected returns and assumes 2.7244% volatility on return distribution over the 90 days horizon. Simply put, 24% of stocks are less volatile than Kilitch, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Kilitch Drugs Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kilitch Drugs' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Kilitch Drugs Limited, and traders can use it to determine the average amount a Kilitch Drugs' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0331
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | KILITCH |
Estimated Market Risk
| 2.72 actual daily | 24 76% of assets are more volatile |
Expected Return
| -0.09 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Kilitch Drugs is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kilitch Drugs by adding Kilitch Drugs to a well-diversified portfolio.
Kilitch Drugs Fundamentals Growth
Kilitch Stock prices reflect investors' perceptions of the future prospects and financial health of Kilitch Drugs, and Kilitch Drugs fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Kilitch Stock performance.
| Return On Equity | 0.0832 | ||||
| Return On Asset | 0.0566 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.02 % | ||||
| Current Valuation | 4.64 B | ||||
| Shares Outstanding | 16.08 M | ||||
| Price To Book | 2.61 X | ||||
| Price To Sales | 3.32 X | ||||
| Revenue | 1.54 B | ||||
| Gross Profit | 641.83 M | ||||
| EBITDA | 286.33 M | ||||
| Net Income | 193.54 M | ||||
| Cash And Equivalents | 1.34 M | ||||
| Total Debt | 316.46 M | ||||
| Book Value Per Share | 109.62 X | ||||
| Cash Flow From Operations | (56.69 M) | ||||
| Earnings Per Share | 10.27 X | ||||
| Total Asset | 2.4 B | ||||
| Retained Earnings | 842.33 M | ||||
About Kilitch Drugs Performance
By evaluating Kilitch Drugs' fundamental ratios, stakeholders can gain valuable insights into Kilitch Drugs' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Kilitch Drugs has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Kilitch Drugs has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Kilitch Drugs is entity of India. It is traded as Stock on NSE exchange.Things to note about Kilitch Drugs Limited performance evaluation
Checking the ongoing alerts about Kilitch Drugs for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Kilitch Drugs Limited help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Kilitch Drugs generated a negative expected return over the last 90 days | |
| Kilitch Drugs is unlikely to experience financial distress in the next 2 years | |
| Kilitch Drugs Limited has accumulated about 1.34 M in cash with (56.69 M) of positive cash flow from operations. | |
| Roughly 75.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Kilitch Drugs Standalone September 2024 Net Sales at Rs 45.35 crore, up 43.63 percent Y-o-Y - Moneycontrol |
- Analyzing Kilitch Drugs' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Kilitch Drugs' stock is overvalued or undervalued compared to its peers.
- Examining Kilitch Drugs' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Kilitch Drugs' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Kilitch Drugs' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Kilitch Drugs' stock. These opinions can provide insight into Kilitch Drugs' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Kilitch Stock analysis
When running Kilitch Drugs' price analysis, check to measure Kilitch Drugs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kilitch Drugs is operating at the current time. Most of Kilitch Drugs' value examination focuses on studying past and present price action to predict the probability of Kilitch Drugs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kilitch Drugs' price. Additionally, you may evaluate how the addition of Kilitch Drugs to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |